Designed to help prevent the spread of HIV/AIDS in sub-Saharan Africa and India, MEMSCap smart electronic medication packaging system tracks each time the medication bottle is opened.
26 January 2015 | Packaging World
People with HIV who experienced extensive immune deficiency or who used early antiretroviral drugs before the advent of combination highly-active antiretroviral therapy (HAART) in the mid-90s may be at greater risk for developing anal cancer, according to a retrospective analysis published in the January 28 edition of AIDS.
23 January 2015 | HIVandHepatitis.com
San Francisco is already making progress when it comes to HIV prevention, treatment and retention. In 2006, San Francisco had 517 new HIV cases; by 2013, that number dropped to 359, a 30 percent decrease. The number of deaths almost halved between 2006 and 2013, going from 327 to 182. Additionally, compared to the United States, San Francisco is faring better in multiple aspects of the HIV care continuum: in 2012, 82 percent of HIV positive individuals in the U.S. were aware of their status; in San Francisco, that number was 94 percent.
11 December 2014 | Huffington Post
The CDC has reframed the HIV treatment cascade figures to highlight the various reasons why only 30 percent of Americans have a fully suppressed virus.
03 December 2014 | POZ
We have been told of ARV stock-outs that resulted in patients having to interrupt HIV medication due to problems in drug supply. It is difficult to understand why a UK clinic would allow problems to develop to the point that this happened not just once, but several times.
01 December 2014 | HIV i-Base
Just 30 percent of Americans living with HIV have the virus in check, putting others at risk of infection, U.S. health officials said yesterday. The report by the U.S. Centers for Disease Control and Prevention (CDC) found that 840,000 of the 1.2 million people infected with HIV in 2011 were not consistently taking anti-HIV drugs that keep the virus suppressed at very low levels.
26 November 2014 | Reuters
Sizwe Nzima was a high school student in Cape Town, South Africa, when he would pick up the medicine for his HIV-positive grandparents, who had difficulty traveling to the clinic themselves. Because of the long lines, Nzima usually waited hours and often made multiple trips to the clinic before and after school. So there he was, sitting on a hard wooden bench at the clinic one day about four years ago, when he had an idea: Why not start an HIV medicine delivery service?
18 November 2014 | NPR (blog)
FDC drug development is evolving rapidly as the industry gains experience in manufacturing them and ushering them through the review process. The laws have changed towards a more favorable marketing climate. And finally, it is clear that FDCs are more than a way to improve adherence—though that will always be a prominent consideration. FDCs can shift the standard of care towards a more tolerable, patient-friendly, value-oriented approach to treatment, and in the final analysis, that approach to development bodes well for companies, payers, and most importantly, patients.
07 November 2014 | BioPharma Dive
There is no magic formula for achieving 10 years of continuous viral load suppression on antiretroviral therapy in people living with HIV -- even perfect adherence didn't improve the chances of continuously suppressed viral loads, according to a poster analysis of the U.S. Military HIV Natural History Study (NHS) cohort presented at IDWeek 2014 in Philadelphia.
29 October 2014 | TheBody.com
While making medications free can remove barriers to access for individuals who cannot pay for treatment, data suggest that for most people accessing care in industrialized countries, "making medications available for free or low cost will not solve problems with medication non-adherence," according to a presentation by Kevin Volpp from the University of Pennsylvania last week at IDWeek 2014 in Philadelphia.
16 October 2014 | HIVandHepatitis.com